A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin: biophysical and computational approach
- 7 April 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (46) , 40225-40237
Abstract
The binding of corilagin with plasma serum proteins like human serum albumin (HSA) and α-1-acid glycoprotein (AGP) was investigated under physiological conditions. To understand the pharmacological importance of the corilagin molecule, anti-inflammatory activity on mouse macrophages (RAW 264.7) cell lines was studied. This study reveals that corilagin caused an increase in inhibition growth of inflamed macrophages in concentration-dependent manner with an IC50 value of 66 μM. Further, intrinsic fluorescence of HSA and AGP was quenched upon titration of corilagin, and the binding constants obtained from fluorescence emission was found to be Kcorilagin 4.2 ± 0.02 × 105 M−1 which corresponds to the free energy of −7.6 kcal M−1 at 25 °C for a HSA–corilagin complex. Interestingly, corilagin showed binding with AGP, an acute phase protein, and the binding constant was found to be Kcorilagin = 1.5 ± 0.01 × 104 M−1 and its free energy was −5.6 kcal M−1 at 25 °C. Further, the average binding distance, r, between the donor (HSA) and acceptor (corilagin) was calculated and found to be 1.32 nm according to Förster's theory of non-radiation energy transfer. Later, circular dichroism studies emphasized that there are marginal changes in secondary structural conformation of HSA in the presence of corilagin. Corilagin is specifically bound to site I of HSA which was proved by site specific marker, phenylbutazone. Furthermore, the binding details between corilagin and HSA revealed that corilagin was bound to subdomain IIA through multiple interactions like hydrogen bonding and hydrophobic effects. Molecular dynamic studies (MD) also suggest that binding is very precise to site I (IIA domain) on HSA. Also, MD studies showed that HSA–corilagin complex reaches equilibration state at around 4 ns, which proves that the HSA–corilagin complex is stable in nature, hence the experimental and computational results are in agreement. Thus, examining the interaction mechanism of corilagin with plasma proteins may play a critical role in developing corilagin inspired drugs.Keywords
Funding Information
- Anusandhan National Research Foundation (No. SR/SO/BB-0123/2010 and DST-FIST, SB/EMEQ-064/2014)
This publication has 69 references indexed in Scilit:
- Elucidation of the Binding Mechanism of Coumarin Derivatives with Human Serum AlbuminPLOS ONE, 2013
- Probing the Binding Sites of Antibiotic Drugs Doxorubicin and N-(trifluoroacetyl) Doxorubicin with Human and Bovine Serum AlbuminsPLOS ONE, 2012
- Corilagin prevents tert-butyl hydroperoxide-induced oxidative stress injury in cultured N9 murine microglia cellsNeurochemistry International, 2011
- Molecular Interaction Studies of Trimethoxy Flavone with Human Serum AlbuminPLOS ONE, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Polyamine Analogues Bind Human Serum AlbuminBiomacromolecules, 2007
- Structural Basis of the Drug-binding Specificity of Human Serum AlbuminJournal of Molecular Biology, 2005
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- GROMACS: A message-passing parallel molecular dynamics implementationComputer Physics Communications, 1995
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984